| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| colistiméthate sodique 500 000 unités, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| colistiméthate sodique 500 000 unités, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Amifostine 500 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Amifostine 500 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely drotrecogin alfa 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely drotrecogin alfa 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| colistiméthate sodique 1 000 000 unités, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| colistiméthate sodique 1 000 000 unités, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| ceftazidime 500 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| ceftazidime 500 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pénicilline G 1 200 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pénicilline G 1 200 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Amifostine 375 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Amifostine 375 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ceftazidime 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| ceftazidime 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| complexe hémagglutinine-toxine botulique de type A 500 unités, pour injection (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| complexe hémagglutinine-toxine botulique de type A 500 unités, pour injection (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| pénicilline g 600 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pénicilline g 600 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Epirubicin hydrochloride 10 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Epirubicin hydrochloride 10 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ceftriaxone 250 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| ceftriaxone 250 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ceftriaxone 1 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ceftriaxone 1 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| ceftriaxone 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ceftriaxone 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely azathioprine 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely azathioprine 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| capréomycine 1 g, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| capréomycine 1 g, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| cefpirome 1 g, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| cefpirome 1 g, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| amoxicilline 250 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| amoxicilline 250 mg, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Agalsidase beta 35 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Agalsidase beta 35 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| cefpirome 2 g, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| cefpirome 2 g, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| amoxicilline 1 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| amoxicilline 1 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Mitomycin 20 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Mitomycin 20 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Fludarabine phosphate 50 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Fludarabine phosphate 50 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Mycophenolate mofetil (as mycophenolate mofetil hydrochloride) 500 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Mycophenolate mofetil (as mycophenolate mofetil hydrochloride) 500 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| idarubicin hydrochloride 5mg powder for injection solution vial (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| idarubicin hydrochloride 5mg powder for injection solution vial (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Ifosfamide 1 g powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Ifosfamide 1 g powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pantoprazole 40 mg, fiole de poudre pour injection (médicament clinique) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pantoprazole 40 mg, fiole de poudre pour injection (médicament clinique) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Lanreotide (as lanreotide acetate) 30 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Lanreotide (as lanreotide acetate) 30 mg powder for suspension for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| idarubicin hydrochloride 10mg powder for injection solution vial (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| idarubicin hydrochloride 10mg powder for injection solution vial (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Ifosfamide 2 g powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Ifosfamide 2 g powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely lenograstim 13.4 million unit/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely lenograstim 13.4 million unit/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely remifentanil (as remifentanil hydrochloride) 5 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely remifentanil (as remifentanil hydrochloride) 5 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pipéracilline 4 g/tazobactam 500 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| pipéracilline 4 g/tazobactam 500 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pipéracilline 4 g/tazobactam 500 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely thiopental sodium 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely thiopental sodium 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely melphalan (as melphalan hydrochloride) 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely melphalan (as melphalan hydrochloride) 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely sodium nitroprusside dihydrate 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely sodium nitroprusside dihydrate 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely octreotide (as octreotide acetate) 10 milligram/1 vial powder for conventional release suspension for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely octreotide (as octreotide acetate) 10 milligram/1 vial powder for conventional release suspension for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Leuprolide acetate 11.25 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Leuprolide acetate 11.25 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely octreotide (as octreotide acetate) 20 milligram/1 vial powder for conventional release suspension for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely octreotide (as octreotide acetate) 20 milligram/1 vial powder for conventional release suspension for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Leuprolide acetate 3.75 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Leuprolide acetate 3.75 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| topotecan 4mg powder for infusion solution vial (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| topotecan 4mg powder for infusion solution vial (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| vancomycine 500 mg, fiole de poudre pour perfusion (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| vancomycine 500 mg, fiole de poudre pour perfusion (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely vindesine sulfate 5 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely vindesine sulfate 5 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely omeprazole (as omeprazole sodium) 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely omeprazole (as omeprazole sodium) 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely palivizumab 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely palivizumab 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely porfimer sodium 75 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely porfimer sodium 75 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Palivizumab 50 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Palivizumab 50 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely peginterferon alfa-2b 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely peginterferon alfa-2b 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Treosulfan 5 g powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Treosulfan 5 g powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely vecuronium bromide 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely vecuronium bromide 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
FHIR